Financials data is unavailable for this security.
View more
Year on year Celon Pharma SA grew revenues 11.29% from 194.59m to 216.57m while net income improved from a loss of 39.28m to a smaller loss of 28.12m.
| Gross margin | 70.12% |
|---|---|
| Net profit margin | -21.69% |
| Operating margin | -20.86% |
| Return on assets | -7.79% |
|---|---|
| Return on equity | -9.82% |
| Return on investment | -9.03% |
More ▼
Cash flow in PLNView more
In 2023, cash reserves at Celon Pharma SA fell by 50.54m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 8.31m. In addition the company used 21.64m on investing activities and also paid 20.59m in financing cash flows.
| Cash flow per share | 0.1617 |
|---|---|
| Price/Cash flow per share | 179.04 |
| Book value per share | 9.00 |
|---|---|
| Tangible book value per share | 8.77 |
More ▼
Balance sheet in PLNView more
| Current ratio | 2.61 |
|---|---|
| Quick ratio | 2.27 |
| Total debt/total equity | 0.0332 |
|---|---|
| Total debt/total capital | 0.0321 |
More ▼
Growth rates in PLN
Year on year, growth in dividends per share fell -11.11% while earnings per share excluding extraordinary items rose 28.44%. Additionally, five year annualized dividend per share growth ranks highest in its industry.
| Div yield(5 year avg) | 0.43% |
|---|---|
| Div growth rate (5 year) | -19.73% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -51.54 |
More ▼
